William J Jacobs

US Patent:

7722861, May 25, 2010

Filed:

Jan 24, 2003

Appl. No.:

10/351452

Inventors:

William R. Jacobs - Pelham NY, US
Tsungda Hsu - Bronx NY, US
Stoyan Bardarov - Bronx NY, US
Svetoslav Bardarov, legal representative - Worcester MA, US
Vasan Sambandamurthy - Bronx NY, US

International Classification:

A01N 63/00
A61K 48/00
A61K 39/04

US Classification:

424 932, 536 231, 536 237, 435243, 4352531, 435440, 424 91, 424 92, 4241841, 4241851, 4241901, 4242341, 4242481

Abstract:

Non-naturally occurring mycobacteria in the complex are provided. These mycobacteria have a deletion of an RD1 region or a region controlling production of a vitamin, and exhibit attenuated virulence in a mammal when compared to the mycobacteria without the deletion. Also provided are non-naturally occurring mycobacteria that have a deletion of a region controlling production of lysine, and mycobacteria comprising two attenuating deletions. Vaccines comprising these mycobacteria are also provided, as are methods of protecting mammals from virulent mycobacteria using the vaccines. Also provided are methods of preparing these vaccines which include the step of deleting an RD1 region or a region controlling production of a vitamin from a mycobacterium in the complex.

US Patent:

20050260232, Nov 24, 2005

Filed:

Apr 19, 2005

Appl. No.:

11/109056

Inventors:

William Jacobs - Pelham NY, US
Barry Bloom - Cambridge MA, US
Mary Hondalus - Crawford GA, US
Samantha Sampson - Brookline MA, US
Vasan Sambandamurthy - Bronx NY, US

International Classification:

A61K039/04
C12N001/21

US Classification:

424248100, 435252300

Abstract:

Non-naturally occurring mycobacteria in the complex are provided. These mycobacteria have a deletion of an RD1 region or a region controlling production of a vitamin, and exhibit attenuated virulence in a mammal when compared to the mycobacteria without the deletion. Also provided are non-naturally occurring mycobacteria that have a deletion of a region controlling production of lysine, and mycobacteria comprising two attenuating deletions. Vaccines comprising these mycobacteria are also provided, as are methods of protecting mammals from virulent mycobacteria using the vaccines. Also provided are methods of preparing these vaccines which include the step of deleting an RD1 region or a region controlling production of a vitamin or the amino acids leucine and lysine from a mycobacterium in the complex. Embodiments of these mycobacteria, vaccines and methods, encompassing mycobacteria comprising a leucine auxotrophy and a pantothenate auxotrophy, are also provided.

US Patent:

20070202131, Aug 30, 2007

Filed:

Jan 23, 2004

Appl. No.:

10/542958

Inventors:

William Jacobs - Pelham NY, US
Tsungda Hsu - Bronx NY, US
Vasan Sambandamurthy - Singapore, SG
Sheldon Morris - Beltsville MD, US
Stoyan Bardarov - Worcester MA, US

Assignee:

HOWARD HUGHES MEDICAL INSTITUTE - Chevy Chase MD
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY - Bronx NY

International Classification:

A61K 39/04
C12N 1/21

US Classification:

424248100, 514047000, 514561000, 435252300

Abstract:

Methods of treating a mammal that is deficient in CD4 and/or CD8 lymphocytes are provided. The methods comprise inoculating the mammal with an attenuated mycobacterium in the complex. In these methods, the mycobacterium comprises two deletions, wherein a virulent mycobacterium in the complex having either deletion exhibits attenuated virulence. Use of these mycobacteria for the manufacture of a medicament for the treatment of mammals deficient in CD4 and/or CD8 lymphocytes is also provided.

US Patent:

20080254061, Oct 16, 2008

Filed:

Jan 11, 2006

Appl. No.:

11/794373

Inventors:

William R. Jacobs - Pelham NY, US
Norman L. Letvin - Newton MA, US
Mark Cayabyab - Boston MA, US
Barton F. Haynes - Durham NC, US
Jae-Sung Yu - Durham NC, US

International Classification:

A61K 39/21
C12N 1/21
C12N 1/20

US Classification:

4242001, 4352523, 4352531, 4242081

Abstract:

Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided are expressing an HIV-1 antigen. Further provided are vaccines capable of inducing an immune response in a mammal against HIV-1 and the malarial pathogen. Additionally provided are methods of inducing an immune response in a mammal against HIV-1 and a malarial pathogen. Also provided are methods of inducing an immune response in a mammal against HIV-1. The methods comprise infecting the mammal with any of the above-described mycobacteria.

US Patent:

20080268541, Oct 30, 2008

Filed:

Jan 12, 2006

Appl. No.:

11/794372

Inventors:

William R. Jacobs - Pelham NY, US
Glenn J. Fennelly - New York NY, US

International Classification:

C12N 15/85
C12N 5/06
C12N 1/21
C12N 15/11

US Classification:

435455, 4352523, 435325, 4353201

Abstract:

Provided are mycobacteria comprising a recombinant gene operably liked to a mammalian promoter that directs expression of the recombinant gene from a mammalian cell. Also provided are mammalian cells comprising the above mycobacteria. Additionally provided are mycobacterial plasmids capable of replication in a mycobacterium. Further provided are methods of expressing a recombinant gene in a mammalian cell.

US Patent:

59687339, Oct 19, 1999

Filed:

Jan 28, 1998

Appl. No.:

9/014560

Inventors:

Barry R. Bloom - Hastings on Hudson NY
Ronald W. Davis - Palo Alto CA
William R. Jacobs - Bronx NY
Richard A. Young - Winchester MA
Robert N. Husson - Takoma Park MD

Assignee:

Albert Einstein College of Medicine of Yeshiva University - Bronx NY
The Board of Trustees of the Leland Stanford, Jr. University - Stanford CA
Whitehead Institute for Biomedical Research - Cambridge MA

International Classification:

C12Q 170
C07H 2104

US Classification:

435 5

Abstract:

Recombinant mycobacterial vaccine vehicles capable of expressing DNA of interest which encodes at least one protein antigen for at least one pathogen against which an immune response is desired and which can be incorporated into the mycobacteria or stably integrated into the mycobacterial genome. The vaccine vehicles are useful for administration to mammalian hosts for purposes of immunization. A recombinant vector which replicates in E. coli but not in mycobacteria is also disclosed. The recombinant vector includes 1) a mycobacterial gene or portions thereof, necessary for recombination with homologous sequences in the genome of mycobacteria transformed with the recombinant plasmid; 2) all or a portion of a gene which encodes a polypeptide or protein whose expression is desired in mycobacteria transformed with the recombinant plasmid; 3) DNA sequences necessary for replication and selection in E. coli; and 4) DNA sequences necessary for selection in mycobacteria (e. g. , drug resistance).

US Patent:

55040055, Apr 2, 1996

Filed:

Jun 5, 1989

Appl. No.:

7/361944

Inventors:

Barry R. Bloom - Hastings on Hudson NY
Ronald W. Davis - Palo Alto CA
William R. Jacobs - Bronx NY
Richard A. Young - Winchester MA
Robert N. Husson - Takoma Park MD

Assignee:

Albert Einstein College of Medicine of Yeshiva University - Bronx NY
The Board of Trustees of the Leland Stanford, Jr. University - Stanford CA
Whitehead Institute for Biomedical Research - Cambridge MA

International Classification:

C12N 1564
C12N 1566
C12N 1574

US Classification:

4352531

Abstract:

Recombinant mycobacterial vaccine vehicles capable of expressing DNA of interest which encodes at least one protein antigen for at least one pathogen against which an immune response is desired and which can be incorporated into the mycobacteria or stably integrated into the mycobacterial genome. The vaccine vehicles are useful for administration to mammalian hosts for purposes of immunization. A recombinant vector which replicates in E. coli but not in mycobacteria is also disclosed. The recombinant vector includes 1) a mycobacterial gene or portions thereof, necessary for recombination with homologous sequences in the genome of mycobacteria transformed with the recombinant plasmid; 2) all or a portion of a gene which encodes a polypeptide or protein whose expression is desired in mycobacteria transformed with the recombinant plasmid; 3) DNA sequences necessary for replication and selection in E. coli; and 4) DNA sequences necessary for selection in mycobacteria (e. g. , drug resistance).

US Patent:

58540555, Dec 29, 1998

Filed:

Jun 5, 1995

Appl. No.:

8/463942

Inventors:

Barry R. Bloom - Hastings on Hudson NY
William R. Jacobs - Bronx NY
Ronald W. Davis - Palo Alto CA
Richard A. Young - Winchester MA
Robert N. Husson - Takoma Park MD

Assignee:

Albert Einstein College of Medicine of Yeshiva University, a Division of
Yeshiva University - Bronx NY

International Classification:

C12N 1564
C12N 1566
C12N 1574

US Classification:

4352531

Abstract:

Recombinant mycobacterial vaccine vehicles capable of expressing DNA of interest which encodes at least one protein antigen for at least one pathogen against which an immune response is desired and which can be incorporated into the mycobacteria or stably integrated into the mycobacterial genome. The vaccine vehicles are useful for administration to mammalian hosts for purposes of immunization. A recombinant vector which replicates in E. coli but not in mycobacteria is also disclosed. The recombinant vector includes 1) a mycobacterial gene or portions thereof, necessary for recombination with homologous sequences in the genome of mycobacteria transformed with the recombinant plasmid; 2) all or a portion of a gene which encodes a polypeptide or protein whose expression is desired in mycobacteria transformed with the recombinant plasmid; 3) DNA sequences necessary for replication and selection in E. coli; and 4) DNA sequences necessary for selection in mycobacteria (e. g. , drug resistance).